These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 22982663)

  • 1. EGFR delE709_T710insD: a rare but potentially EGFR inhibitor responsive mutation in non-small-cell lung cancer.
    Ackerman A; Goldstein MA; Kobayashi S; Costa DB
    J Thorac Oncol; 2012 Oct; 7(10):e19-20. PubMed ID: 22982663
    [No Abstract]   [Full Text] [Related]  

  • 2. Erlotinib response in an NSCLC patient with a novel compound G719D+L861R mutation in EGFR.
    Berge EM; Aisner DL; Doebele RC
    J Thorac Oncol; 2013 Sep; 8(9):e83-4. PubMed ID: 23945392
    [No Abstract]   [Full Text] [Related]  

  • 3. Personalized medicine and inhibition of EGFR signaling in lung cancer.
    Gazdar AF
    N Engl J Med; 2009 Sep; 361(10):1018-20. PubMed ID: 19692681
    [No Abstract]   [Full Text] [Related]  

  • 4. Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations.
    Costa DB; Schumer ST; Tenen DG; Kobayashi S
    J Clin Oncol; 2008 Mar; 26(7):1182-4; author reply 1184-6. PubMed ID: 18309959
    [No Abstract]   [Full Text] [Related]  

  • 5. EGFR exon 18 delE709_T710insD mutated stage IV lung adenocarcinoma with response to afatinib.
    Ibrahim U; Saqib A; Atallah JP
    Lung Cancer; 2017 Jun; 108():45-47. PubMed ID: 28625646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of afatinib treatment for lung adenocarcinoma harboring exon 18 delE709_T710insD mutation.
    Iwamoto Y; Ichihara E; Hara N; Nakasuka T; Ando C; Umeno T; Hirabae A; Maeda Y; Kiura K
    Jpn J Clin Oncol; 2019 Aug; 49(8):786-788. PubMed ID: 31187861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Time for molecularly targeted maintenance therapy for non-small-cell lung cancer?
    Stinchcombe TE; Ramalingam SS
    Lancet Oncol; 2010 Jun; 11(6):500-1. PubMed ID: 20493770
    [No Abstract]   [Full Text] [Related]  

  • 8. Serum concentrations of Erlotinib at a dose of 25 mg daily.
    Costa DB; Kobayashi S; Yeo WL; Hamada A
    J Thorac Oncol; 2010 Aug; 5(8):1311-2. PubMed ID: 20661096
    [No Abstract]   [Full Text] [Related]  

  • 9. NICE guidance on erlotinib for first-line treatment of EGFR-TK mutation-positive advanced or metastatic non-small-cell lung cancer.
    Dillon B; Naidoo B; Knight H; Clark P
    Lancet Oncol; 2012 Aug; 13(8):764-5. PubMed ID: 23024988
    [No Abstract]   [Full Text] [Related]  

  • 10. The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations.
    Heon S; Yeap BY; Lindeman NI; Joshi VA; Butaney M; Britt GJ; Costa DB; Rabin MS; Jackman DM; Johnson BE
    Clin Cancer Res; 2012 Aug; 18(16):4406-14. PubMed ID: 22733536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EGFR-mutated lung cancer with T790M-acquired resistance in the brain and histologic transformation in the lung.
    Scher KS; Saldivar JS; Fishbein M; Marchevsky A; Reckamp KL
    J Natl Compr Canc Netw; 2013 Sep; 11(9):1040-4. PubMed ID: 24029120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clairvoyance or reliable prediction of the future?
    van Zandwijk N; van de Vijver MJ
    Ann Oncol; 2007 Mar; 18(3):407-8. PubMed ID: 17322538
    [No Abstract]   [Full Text] [Related]  

  • 13. Genetic and proteomic features associated with survival after treatment with erlotinib in first-line therapy of non-small cell lung cancer in Eastern Cooperative Oncology Group 3503.
    Amann JM; Lee JW; Roder H; Brahmer J; Gonzalez A; Schiller JH; Carbone DP
    J Thorac Oncol; 2010 Feb; 5(2):169-78. PubMed ID: 20035238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of sensitivity to gefitinib/erlotinib for EGFR mutations in NSCLC based on structural interaction fingerprints and multilinear principal component analysis.
    Zou B; Lee VHF; Yan H
    BMC Bioinformatics; 2018 Mar; 19(1):88. PubMed ID: 29514601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The predictive value of EGFR status in non-small cell lung cancer patients treated with EGFR-TKIs].
    Wang Y; Liu H; Chen J
    Zhongguo Fei Ai Za Zhi; 2010 Apr; 13(4):375-9. PubMed ID: 20677568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGFR exon 19 deletion mutations and systemic/central nervous system miliary metastasis: clinical correlations and response to therapy.
    Poonia S; Berge EM; Aisner DL; Damek D; Doebele RC
    Clin Lung Cancer; 2014 Sep; 15(5):387-9. PubMed ID: 24894944
    [No Abstract]   [Full Text] [Related]  

  • 17. Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
    Chang LC; Lim CK; Chang LY; Chen KY; Shih JY; Yu CJ
    Eur J Cancer; 2019 Sep; 119():77-86. PubMed ID: 31425965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel EGFR nonsense mutation in a non-small-cell lung cancer (NSCLC) patient who did not derive any clinical benefit with combination chemotherapy and erlotinib.
    González Manzano R; Martínez Navarro E; Eugenieva E; Fernández Morejón FJ; Farré J; Brugarolas A
    Clin Transl Oncol; 2008 Jul; 10(7):442-4. PubMed ID: 18628075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.
    Nakagawa T; Takeuchi S; Yamada T; Nanjo S; Ishikawa D; Sano T; Kita K; Nakamura T; Matsumoto K; Suda K; Mitsudomi T; Sekido Y; Uenaka T; Yano S
    Mol Cancer Ther; 2012 Oct; 11(10):2149-57. PubMed ID: 22844075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors for brain metastases from non-small cell lung cancer with EGFR mutation: influence of stable extracranial disease and erlotinib therapy.
    Sekine A; Satoh H; Iwasawa T; Tamura K; Hayashihara K; Saito T; Kato T; Arai M; Okudela K; Ohashi K; Ogura T
    Med Oncol; 2014 Oct; 31(10):228. PubMed ID: 25208818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.